Biosplice Therapeutics, Inc.
Clinical trials sponsored by Biosplice Therapeutics, Inc., explained in plain language.
-
New knee injection shows promise for osteoarthritis pain
Disease control CompletedThis study tested a new drug called lorecivivint (SM04690) injected into the knee for people with moderate to severe knee osteoarthritis. 101 participants received two injections six months apart and were followed for a year. The goal was to see if the drug is safe and improves b…
Phase: PHASE2 • Sponsor: Biosplice Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
One-Shot knee treatment could ease arthritis pain for over a year
Symptom relief CompletedThis study tested a single injection of lorecivivint into the knee joint of 501 people with moderate-to-severe knee osteoarthritis. The goal was to see if it reduces pain and improves function over 56 weeks compared to a placebo. Participants reported their pain levels weekly, an…
Phase: PHASE3 • Sponsor: Biosplice Therapeutics, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 09:05 UTC
-
One shot to ease knee pain? new drug shows promise in large trial
Symptom relief CompletedThis study tested a single injection of a drug called lorecivivint in the knee joint of 496 people with moderate to severe knee osteoarthritis. The goal was to see if it reduces pain and improves function compared to a placebo (fake injection) over 28 weeks. Participants reported…
Phase: PHASE3 • Sponsor: Biosplice Therapeutics, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 09:02 UTC